- Oops!Something went wrong.Please try again later.
Shares of Edwards Lifesciences (NYSE:EW) decreased 4.5% in after-market trading after the company reported Q4 results.
Earnings per share decreased 65.75% over the past year to $0.50, which missed the estimate of $0.53.
Revenue of $1,192,000,000 rose by 1.53% year over year, which beat the estimate of $1,190,000,000.
Edwards Lifesciences Sees FY21 Adj. EPS $2-$2.20 vs $2.15 Estimate, Sales $4.9B-$5.3B vs $5.09B Est.
Edwards Lifesciences Sees Q1 Adj. EPS $0.43-$0.50 vs $0.50 Estimate, Sales $1.1B-$1.2B vs $1.21B Est.
How To Listen To The Conference Call
Date: Jan 27, 2021
Time: 05:00 PM
Recent Stock Performance
52-week high: $242.98
Company's 52-week low was at $66.23
Price action over last quarter: Up 4.06%
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. Its key products include surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters and retractors, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.